Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Feb 26, 2019; 11(2): 84-99
Published online Feb 26, 2019. doi: 10.4252/wjsc.v11.i2.84
Published online Feb 26, 2019. doi: 10.4252/wjsc.v11.i2.84
Anti-inflammatory potential of human corneal stroma-derived stem cells determined by a novel in vitro corneal epithelial injury model
Mariana Lizeth Orozco Morales, Nagi M Marsit, Owen D McIntosh, Andrew Hopkinson, Laura E Sidney, Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, NG7 2UH, United Kingdom
Author contributions: Orozco Morales ML performed the majority of the data acquisition and analysis; Marsit NM processed all amniotic membrane used and helped with acquisition of data; McIntosh OD contributed to conception of the study and acquisition of data; Hopkinson A contributed to conception of the study; Sidney LE contributed to conception of the study, design of experiments, data acquisition, data analysis, and interpretation of data; all authors contributed to drafting the article, making revisions, and had final approval of the manuscript.
Institutional review board statement: Human corneoscleral rims and human AM were used with approval by the Nottingham Research Ethics Committee (Ethics approval numbers: 07/H0403/140 and OY110101, respectively).
Informed consent statement: All corneal tissue was supplied anonymously through Manchester Eye Bank, and all informed consent forms are held at this institution. For amniotic membrane, all donors provided written informed consent prior to tissue collection. During research studies all tissue was anonymised to the researchers.
Conflict-of-interest statement: There are no potential conflicts of interest relevant to this study reported by the authors.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Laura E Sidney, MSc, PhD, Senior Research Fellow, Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Queen’s Medical Centre Campus, Nottingham NG7 2UH, United Kingdom. laura.sidney@nottingham.ac.uk
Telephone: +44-115-8230459
Received: July 24, 2018
Peer-review started: July 24, 2018
First decision: October 5, 2018
Revised: November 1, 2018
Accepted: January 1, 2019
Article in press: January 1, 2019
Published online: February 26, 2019
Processing time: 217 Days and 16.6 Hours
Peer-review started: July 24, 2018
First decision: October 5, 2018
Revised: November 1, 2018
Accepted: January 1, 2019
Article in press: January 1, 2019
Published online: February 26, 2019
Processing time: 217 Days and 16.6 Hours
Core Tip
Core tip: We designed a novel in vitro inflammation model of the human corneal surface using human corneal epithelial cells treated with 20% (v/v) ethanol, followed by stimulation with 1 ng/mL interleukin-1β. We then used this model to demonstrate the anti-inflammatory and regenerative healing properties of human cornea stroma-derived stem cells seeded on an amniotic membrane substrate in a co-culture model. This study is the first step in building a topical regenerative therapy for the treatment of inflammatory disorders of the front of the eye.